ABI-009 (Nab-rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A phase 2, open-label study of ABI-009 (nab-Rapamycin) in patients with recurrent high grade
glioma following prior therapy and subjects with newly diagnosed glioblastoma. ABI-009 will
be tested as single agent or in combination with standard therapies.